81
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Anti-NuMA antibodies in a psoriatic patient: Considerations about clinical relevance and effect of infliximab treatment

, , &
Pages 127-129 | Received 01 Aug 2008, Accepted 10 Sep 2008, Published online: 17 Feb 2009

References

  • Grypiotis, P.; Ruffatti, A.; Tonello, M.; Winzler, C.; Radu, C.; Zampieri, S.; Favaro, M.; Calligaro, A.; Todesco, S. Significato clinico dei quadri fluoroscopici specifici per il fuso mitotico in pazienti affetti da malattie reumatiche. Reumatismo 2002, 54 (3), 232–237.
  • Bonaci-Nikolic, B.; Andrejevic, S.; Bukilica, M.; Urosevic, I.; Nikolic, M. Autoantibodies to mitotic apparatus: Association with other autoantibodies and their clinical significance. J. Clin. Immunol. 2006, 26(5), 438–446.
  • Mozo, L.; Gutiérrez, C.; Gómez, J. antibodies to mitotic spindle apparatus: Clinical significance of NuMA and HsEg5 autoantibodies. J. Clin. Immunol. 2008, 28 (4), 285–290.
  • Zeng, C. NuMA: a nuclear protein involved in mitotic centrosome function. Microsc. Res. Tech. 2000, 49(5), 467–477.
  • Whitehead, C.M.; Rattner, J.B. Expanding the role of HsEg5 within the mitotic and post-mitotic phases of the cell cycle. J. Cell. Sci. 1998, 111 (Pt. 17), 2551–2561.
  • Bernardini, S.; Infantino, M.; Bellincampi, L.; Nuccetelli M.; Afeltra, A.; Lori, R.; Biroccio, A.; Urbani, A.; Federici, G. Screening of antinuclear antibodies: Comparison between enzyme immunoassay based on nuclear homogenates, purified or recombinant antigens and immunofluorescence assay. Clin. Chem. Lab. Med. 2004, 42 (10), 1155–1160.
  • Sinclair, D.; Saas, M.; Williams, D.; Hart, M.; Goswami, R. Can an ELISA replace immunofluorescence for the detection of anti-nuclear antibodies? The routine use of anti-nuclear antibody screening ELISAs. Clin. Lab. 2007, 53(3–4), 183–191.
  • Huang, W.; Cordoro, K.M.; Taylor, S.L.; Feldman, S.R. To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis. J. Am. Acad. Dermatol. 2008, 58(6), 970–977.
  • Atzeni, F.; Turiel, M.; Capsoni, F.; Doria, A.; Meroni, P.; Sarzi-Puttini, P. Autoimmunity and anti-TNF-alpha agents. Ann. N. Y. Acad. Sci. 2005, 1051, 559–569.
  • De Bandt, M. Lessons for lupus from tumour necrosis factor blockade. Lupus 2006, 15 (11), 762–767.
  • Ramos-Casals, M.; Brito-Zerón, P.; Muñoz, S.; Soria, N.; Galiana, D.; Bertolaccini, L.; Cuadrado, M.J.; Khamashta, M.A. Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases. Medicine (Baltimore) 2007, 86 (4), 242–251.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.